Spencer's Retail Q4 loss narrows to Rs 68 cr
on Thursday reported narrowing of its consolidated net loss to Rs 68.40 crore for March
quarter
FY25. The company had incurred a loss of Rs 80.69 crore in the January-March period a year ago, according to a regulatory filing from Spencer's Retail, a RP
Sanjiv Goenka
firm.
However,
revenue
from operations was down to Rs 411.87 crore in March quarter from Rs 546.79 crore a year ago. Total expenses were lower by 22.2 per cent to Rs 491.60 crore in the quarter. Total income, which includes other income, fell 23.22 per cent to Rs 423.13 crore.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
New Container Houses Indonesia (Prices May Surprise You)
Container House | Search Ads
Search Now
In FY25, Spencer's Retail narrowed its net loss to Rs 246.36 crore from Rs 266.15 crore a year ago. Total income was at Rs 2,098.72 crore as against Rs 2,370.62 crore earlier.
There was a drop in topline due to closure of 47 stores of Spencer's in Q2, the company said in its investor presentation.
"Spencer's delivered a strong operational performance for FY25 on the back of the strategic decisions and actions taken in H1 to focus on key geographies and optimize the costs in line with the resulting scale.
Live Events
"The results of these actions flowed through in H2 with all key operational metrics improving and yielding a significant (4X) improvement in
EBITDA
for FY 25," Chairman Shashwat Goenka said.
This puts the company in a good shape to drive growth across Natures Basket & Spencer's, both in the offline and online verticals, he added.
Spencer's, which started its quick delivery proposition JIFFY in Kolkata in January has witnessed good traction with strong growth in both orders and user base.
"We are taking this to a few other cities in UP and West Bengal in the current fiscal," he said.
The total store count along with Natures Basket is 89 across India.
Shares
of Spencer's Retail on Thursday settled at Rs 65.51 apiece on BSE, down 0.02 per cent from the previous close.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
24 minutes ago
- Economic Times
Mumbai property market maintains steady pace in July on demand, infra boost
Synopsis Mumbai's property market remained robust in July, mirroring last year's momentum with 12,510 deals. Stamp duty collections increased by 5.4% to Rs 1,121 crore, driven by sustained end-user demand and a preference for larger, premium homes. Infrastructure upgrades and stable interest rates continue to fuel buyer confidence, particularly in emerging corridors. Agencies Mumbai, the country's biggest and most expensive property market, remained on firm ground in July, with sustained end-user demand and growing preference for larger, premium homes continuing to shape buying interest levels and ongoing infrastructure upgrades across the city have helped maintain market momentum even after price growth and ready reckoner rates rise that was implemented from April Maximum City registered 12,510 property deals in July, maintaining the momentum witnessed a year ago, while stamp duty collections rose 5.4% to Rs 1,121 crore, showed data from the Inspector General of Registration (IGR), Maharashtra.'Mumbai's residential market continues to show steady buyer confidence, with monthly registrations consistently crossing the 12,000-mark in residential registrations. While there has been some softening in demand for mid-ticket segments, demand for larger homes and properties priced above Rs 5 crore remains strong, supporting healthy revenue collections,' said Shishir Baijal, CMD, Knight Frank marked the tenth consecutive month of registrations staying above the 11,000-mark, a clear indicator of consistent buyer sentiment. On a month-on-month basis property registrations increased by 7% while stamp duty collections increased by 6%. 'The uptick in housing sales highlights how strongly infrastructure upgrades are influencing buyer sentiment. As metro lines, expressways, a new airport, and civic amenities offering strategic connectivity take shape, homebuyers are growing more confident about investing in emerging corridors. The momentum is also driven by diverse residential and commercial growth supported by infra-led development and emerging communities,' said Anuj Goradia, Director, Dosti the January-July period, total registrations rose 5% on-year to 88,570, while stamp duty revenue grew 14% to Rs 7,853 crore, marking the strongest seven-month performance ever on this count. The market continued to be driven by residential demand, with 80% of registrations during the month were for residential share of high-value transactions continued to grow, with properties priced above Rs 5 crore accounting for 6% of all deals in July, compared to 5% a year ago. The mid-market category of Rs 1 crore to Rs 5 crore saw a slight decline in share, however, the category below Rs 1 crore grew up to 1,000 sq ft remained dominant, contributing 82% of all registrations. Within this, the 500–1,000 sq ft segment held steady at 46%, while the 1,000-2,000 sq ft segment rose to 14%.The western and central suburbs continued to drive the market, together accounting for 88% of all registrations. The western suburbs contributed 57%, central suburbs 31%, while South Mumbai's share eased to 6%.
Economic Times
24 minutes ago
- Economic Times
Commercial LPG cylinder price cut by Rs 33; no change in domestic cylinder rates
ANI The reduction is expected to provide relief to small businesses like restaurants, hotels, and food vendors that depend heavily on commercial LPG for daily operations. Oil marketing companies (OMCs) have announced a price cut of Rs 33.50 for 19 kg commercial LPG cylinders, effective August 1. In Delhi, the revised retail price will be Rs 1,631.50. However, there is no change in the cost of 14.2 kg domestic LPG cylinders. This marks yet another adjustment in a series of reductions over recent months. On July 1, the price of commercial LPG was slashed by Rs 58.50, bringing it down to Rs 1,665 per cylinder. Prior to that, OMCs had reduced prices by Rs 24 in June, Rs 41 in April, and Rs 7 in February. March had seen a marginal hike of Rs 6. The latest cut is expected to ease the financial burden on small businesses such as restaurants, hotels, and street food vendors that rely heavily on commercial LPG for their daily operations. While domestic usage accounts for nearly 90% of India's total LPG consumption, the remaining 10% serves commercial, industrial, and automotive sectors. Domestic LPG prices tend to remain stable despite frequent revisions in commercial rates. According to an earlier report of The Economic Times , the average price of India's crude oil basket fell to $64.5 per barrel in May 2025—its lowest in three years. This drop is expected to reduce LPG-related losses for OMCs by around 45% in the coming fiscal year. Since domestic gas pricing is linked to 10% of the crude oil basket, fluctuations in global oil rates significantly influence local fuel economics. India has seen rapid growth in household LPG adoption, with connections doubling over the last decade to reach nearly 33 crore households as of April 2025.
Time of India
28 minutes ago
- Time of India
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Explore courses from Top Institutes in Please select course: Select a Course Category healthcare Project Management Finance Technology Operations Management Artificial Intelligence Data Science Management PGDM Data Science Product Management Degree Others Healthcare Public Policy Design Thinking Cybersecurity Digital Marketing others CXO Leadership MCA MBA Data Analytics Skills you'll gain: Duration: 11 Months IIM Lucknow CERT-IIML Healthcare Management India Starts on undefined Get Details Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 15 Most Beautiful Women in the World Undo "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." Live Events AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
